

REMARKS


The Examiner has requested that corrected drawings be submitted.
New drawings are submitted herewith.

Claims 1-27 are rejected under 35 USC 103(a) as being unpatentable over Lamey (US 5,666,962) in view of Watsuji (GB 2,266,182). Applicants respectfully traverse the rejection. Lamey discloses the use of infrared thermography to monitor the progress of a virus in a patient. Watsuji teaches bioelectronic switches. The references are from divergent fields and are not properly combined. There is no suggestion or motivation in either reference to undertake the Examiner's proposed combination. Moreover, the Watsuji reference only mentions infrared spectroscopy and provides no teaching relative to infrared thermography. Applicants respectfully request the rejection be withdrawn.

All other claims rejected by the Examiner have been canceled.
Applicants submit that the claims are in condition for allowance and requests favorable reconsideration.

If the Examiner has any questions or concerns, the Examiner is invited to contact the undersigned.

Respectfully submitted,



Michael M. Conger
Attorney for Applicants
Registration No. 43,562

Date: January 16, 2003
GlaxoSmithKline
Five Moore Drive, PO Box 13398
Research Triangle Park
North Carolina 27709
Telephone: (919) 483-2474
Facsimile: (919) 483-7988